Psy46 - A Dynamic Approach for Budget Impact Analysis (Bia) in Oncology – The Case of Novel Treatment Combinations for Frontline Transplant-Ineligible Newly Diagnosed Multiple Myeloma (Tie Ndmm)

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2623
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03)

Clinical Cancer Research
Cancer ResearchOncology
2019English

Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates

Cancer Journal
Cancer ResearchOncology
2009English

A Dynamic Approach for Budget Impact Analysis (BIA) in Oncology: Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC) as an Illustrative Example

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy17 - Treatment Regimens for Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Bortezomib-Based Regimens Used as Induction in Newly Diagnosed Multiple Myeloma (Ndmm) Patients Eligible for Stem Cell Transplantation (Sct)The Cost-Utility Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Benefit of Continuous Treatment for Responders With Newly Diagnosed Multiple Myeloma in the Randomized FIRST Trial

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

A Budget Impact Model for the Introduction of Bevacizumab for the Treatment of Newly Diagnosed Glioblastoma Multiforme in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Front-Line Therapies for Elderly Patients With Transplant-Ineligible Multiple Myeloma and High-Risk Cytogenetics in the Era of Novel Agents

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy